Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 9/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.93 |
| ▸ | CES2 | O00748 | 1/20 | 0.93 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.93 |
| ▸ | GLA | P06280 | 1/20 | 0.93 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.93 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.93 |
| ▸ | AADAC | P22760 | 1/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.93 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.93 |
| ▸ | HTT | P42858 | 1/20 | 0.93 |
| ▸ | HTR6 | P50406 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flutamide SCHEMBL3934 | 0.96 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL1461845 | 0.96 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL29349783 | 0.96 | AR (1.00) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL21753660 | 0.95 | AR (0.97) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL28162762 | 0.95 | AR (0.97) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL7104567 | 0.91 | AR (0.90) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| Flutamide SCHEMBL1028216 | 0.89 | AR (0.86) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11512367 | 0.87 | AR (0.83) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL19117466 | 0.86 | AR (0.81) | ARCYP3A4CES2ABCB11ALDH1A1 | |
| SCHEMBL11512254 | 0.86 | AR (0.81) | ARCYP3A4CES2ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392323-A1 | PROSTATE CANCER PROGRESSION INHIBITOR AND PROGRESSION INHIBITION METHOD | Kyoto University (JP) | 2011-12-07 | — | — | EP | claimed |
| US-20110287112-A1 | PROSTATE CANCER PROGRESSION INHIBITOR AND PROGRESSION INHIBITION METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | claimed |
| EP-2392323-A1 | PROSTATE CANCER PROGRESSION INHIBITOR AND PROGRESSION INHIBITION METHOD | Kyoto University (JP) | 2011-12-07 | — | — | EP | disclosed |
| US-20110287112-A1 | PROSTATE CANCER PROGRESSION INHIBITOR AND PROGRESSION INHIBITION METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287112-A1 | PROSTATE CANCER PROGRESSION INHIBITOR AND PROGRESSION INHIBITION METHOD | ACP3, BPHL, AR | AR 3/4885CYP3A4 1124/4885CES2 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.